Patheon

Thermo Fisher Scientific’s state-of-the-art facility in #Groningen, #Netherlands, is dedicated to #biologics #drugdevelopment. It features two buildings—one focused on testing and analytical services, with the other providing #preclinical and #clinical manufacturing space. Home to more than 200 #biopharmaceutical professionals from around the globe, this #biomanufacturing site is centrally located in #Europe and equipped with advanced single-use technologies, including 500 L, 1,000 L, and 2,000 L #bioreactors. Discover more about this facility and our comprehensive #CDMO capabilities by watching our new video. You can also click here to download our #Groningen fact sheet and visitor guide, as well as request a tour: http://spr.ly/6044Q7aSy

In today’s fast-paced and increasingly complex #pharmaceutical landscape, adopting a single, unified #CDMO and #CRO partnership model can reshape how #biotech and #pharma companies tackle challenges in #drugdevelopment. Jennifer Cannon, president of commercial operations for pharma services at Thermo Fisher Scientific, recently shared her insights in the latest issue of World Pharma Today, exploring how solutions like Accelerator™ Drug Development move beyond traditional, multi-partner setups to reduce workflow fragmentation, foster stronger alignment, and empower companies to bring therapies to market with greater speed, cost-efficiency, and adaptability. Read the article to learn more about how this approach accelerates development, reduces costs, and enables companies to deliver #drugs to patients more swiftly: http://spr.ly/6040Q7xvg

According to James Hulvat, time constraints, budget limitations, and #API availability continue to be key challenges in oral solid dose (#OSD) #drugdevelopment and manufacturing. Learn how Thermo Fisher Scientific is helping #biotech and #pharma companies overcome these hurdles with our end-to-end, comprehensive #CDMO and #CRO capabilities. Click here: http://spr.ly/6041QCEVf

From every colleague across Thermo Fisher Scientific, we send you warm wishes for a festive season of celebration with you and your loved ones. Happy holidays and enjoy the New Year!

#Oralsoliddose (#OSD) drug formulations account for approximately 84% of all medications on the market—making critical treatments accessible to patients worldwide. Shervin Hebbi, vice president of oral solid dose North America at Thermo Fisher Scientific, recently shared insights with BioPharma APAC about Thermo Fisher’s #OSD manufacturing site expansions in #Bend, OR, and #Cincinnati, OH, and their impact on #pharma companies working to deliver life-changing medications to patients. Hear from Shervin about how these sites are leveraging technological innovation to help #pharma and #biopharma partners overcome #formulationchallenges and speed up preclinical #drugdevelopment in the #OSD sector: http://spr.ly/6042Q7uPo

The future of #drugdevelopment is here. At Thermo Fisher Scientific, we’re thrilled to stand at the forefront of innovation with our newly launched approach: Accelerator™ Drug Development, 360° #CDMO and #CRO solutions. But how do we compare to other third-party #drugdevelopment and #research partners in this space? In a new video, Jennifer Cannon, our president of commercial operations, pharma services, provides a specific example, showcasing how we’re delivering value for #biotech and #pharma sponsors conducting #clinicaltrials. Watch the video here: http://spr.ly/6042Q2xDn

Leaders across Thermo Fisher Scientific are excited to attend J.P. Morgan’s 43rd Annual Healthcare Conference, taking place January 13-16, 2025 in #SanFrancisco. As the largest #healthcare investment symposium, this invitation-only event connects industry leaders, emerging companies, technology innovators, and the investment community to explore trends, highlight advancements, and drive progress in the #biotech and #pharma space. We look forward to engaging with our peers and showcasing our comprehensive #CDMO and #CRO #drugdevelopment solutions at this year’s show. We’ll see you in #SanFran! To schedule a private 1:1 meeting with a member of our team during this event, click here: http://spr.ly/6041Qau2x

Strategically located within one of India’s #SpecialEconomicZones (#SEZ), our #Ahmedabad facility simplifies and safeguards #clinicaltrial supply for #drugdevelopers worldwide. We’ve recently enhanced our #coldstorage capabilities at this site, now offering expanded storage solutions for 2°C to 8°C to better support your needs in #SouthAsia and beyond. Learn more about this #facility here: http://spr.ly/6042QajNo

A recent oncology-focused study conducted by the Tufts Center for the Study of Drug Development found that an integrated #CDMO and #CRO approach can help reduce #clinical #drugdevelopment timelines by an average of 7-19 months. In a new video, Jennifer Cannon, president of commercial operations, pharma services at Thermo Fisher Scientific, explores these findings and highlights three key benefits sponsors can gain through Accelerator™ Drug Development, including: ▶️ Speed ▶️ Flexibility ▶️ Savings Watch the #video to learn more: http://spr.ly/6041QvOXl

As a well-established and popular #drugformulation, #oralsoliddose (#OSD) products account for approximately 85% of the market. At Thermo Fisher Scientific, we focus on driving #innovation through enhanced formulations and manufacturing efficiency, delivering added value to support our #pharma customers in bringing life-changing medicines to patients. Michelle Logan, our vice president of #drugproduct North America, recently shared her insights on #OSD trends during a roundtable discussion on Pharmaceutical Technology’s “Drug Solutions Podcast” alongside other industry leaders. Listen to the #podcast to learn how our team is strengthening our early #drugdevelopment capabilities to help customers transition seamlessly to #commercialization: http://spr.ly/6049QUZOl